CO5271680A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- CO5271680A1 CO5271680A1 CO01013429A CO01013429A CO5271680A1 CO 5271680 A1 CO5271680 A1 CO 5271680A1 CO 01013429 A CO01013429 A CO 01013429A CO 01013429 A CO01013429 A CO 01013429A CO 5271680 A1 CO5271680 A1 CO 5271680A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- imidazol
- pyridine
- dimethylphenyl
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- -1 C1-6-thio alkyl Chemical group 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- CYFZVRBHAYKDTI-UHFFFAOYSA-N 2-(2-tert-butyl-4-phenyl-1h-imidazol-5-yl)pyridine Chemical compound N1C(C(C)(C)C)=NC(C=2N=CC=CC=2)=C1C1=CC=CC=C1 CYFZVRBHAYKDTI-UHFFFAOYSA-N 0.000 abstract 1
- FIWOARRMYCTVNH-UHFFFAOYSA-N 2-[2-tert-butyl-4-(4-methoxyphenyl)-1h-imidazol-5-yl]pyridine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2N=CC=CC=2)N=C(C(C)(C)C)N1 FIWOARRMYCTVNH-UHFFFAOYSA-N 0.000 abstract 1
- GVGHVFFCFAKXHA-UHFFFAOYSA-N 2-[4-(2-methylphenyl)-2-propyl-1h-imidazol-5-yl]pyridine Chemical compound N1C(CCC)=NC(C=2N=CC=CC=2)=C1C1=CC=CC=C1C GVGHVFFCFAKXHA-UHFFFAOYSA-N 0.000 abstract 1
- IMNYISMEOKVDQO-UHFFFAOYSA-N 2-[4-(3,5-dichlorophenyl)-2-methyl-1h-imidazol-5-yl]pyridine Chemical compound N1C(C)=NC(C=2N=CC=CC=2)=C1C1=CC(Cl)=CC(Cl)=C1 IMNYISMEOKVDQO-UHFFFAOYSA-N 0.000 abstract 1
- WDVMPTRGIDTUDO-UHFFFAOYSA-N 2-[4-(3,5-dimethylphenyl)-2-ethyl-1h-imidazol-5-yl]pyridine Chemical compound N1C(CC)=NC(C=2N=CC=CC=2)=C1C1=CC(C)=CC(C)=C1 WDVMPTRGIDTUDO-UHFFFAOYSA-N 0.000 abstract 1
- HZEZYWLWEUSWLV-UHFFFAOYSA-N 2-[4-(3,5-dimethylphenyl)-2-methyl-1h-imidazol-5-yl]pyridine Chemical compound N1C(C)=NC(C=2N=CC=CC=2)=C1C1=CC(C)=CC(C)=C1 HZEZYWLWEUSWLV-UHFFFAOYSA-N 0.000 abstract 1
- PYDPHZGDXZMGRI-UHFFFAOYSA-N 2-[4-(3,5-dimethylphenyl)-2-propyl-1h-imidazol-5-yl]pyridine Chemical compound N1C(CCC)=NC(C=2N=CC=CC=2)=C1C1=CC(C)=CC(C)=C1 PYDPHZGDXZMGRI-UHFFFAOYSA-N 0.000 abstract 1
- QTXNSOXTUCDWTR-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-5-pyridin-2-yl-1h-imidazol-2-amine Chemical compound CC1=CC(C)=CC(C2=C(N=C(N)N2)C=2N=CC=CC=2)=C1 QTXNSOXTUCDWTR-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula (i) o una de sus sales farmacéuticamente aceptables: <EMI FILE="01013429_1" ID="1" IMF=JPEG >en la que R1 es naftilo, antracenilo o fenilo opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo que consta de halógeno, alcoxi de C1-6, alquil de C1-6-tio, alquilo de C1-6, haloalquilo de C1-6, O-(CH2)m-Ph, S-(CH2)m-Ph, ciano, fenilo y CO2R, en el que R es hidrógeno o alquilo de C1-6, y m es 0-3; o R1 es fenilo o piridilo condensado con un anillo cíclico aromático o no aromático de 5-7 miembros en el que dicho anillo cíclico opcionalmente contiene hasta tres heteroátomos, independientemente seleccionados de N, O y S, y está opcionalmente sustituido con =O; R2 representa hidrógeno, alquilo de C1-6, alcoxi de C1-6, fenilo, haloalquilo de C1-6, halógeno, NH2, NH-alquilo de C1-6, o NH(CH2)n-Ph, en el que n es 0-3;R3 representa alquilo de C1-6, -(CH2)p-CN, -(CH2)p-COOH, -(CH2)p-CONHR4R5, -(CH2)PCOR4, -(CH2)q(OR6)2, -(CH2)p OR4, -(CH2)q-CH=CH-CN, -(CH2)q-CH=CH-CO2H, -(CH2)p-CH=CH-CONHR4R5, (CH2)pNHCOR7 o (CH2)pNR8R9, R4 y R5 son independientemente hidrógeno o alquilo de C1-6; R6 es alquilo de C1-6; R7 es alquilo de C1-7, o arilo, heteroarilo, aril-alquilo de C1-6 o heteroaril-alquilo de C1-6, opcionalmente sustituidos; R8 y R9 se seleccionan independientemente de hidrógeno, alquilo de C1-6, arilo y aril-alquilo de C1-6; p es 0-4;q es 1-4; uno de X1 y X2 es N y el otro es NR10; y R10, es hidrógeno, alquilo de C1-6, o cicloalquilo de C3-7;con la condición de que el compuesto no sea: - 2 -i) 2-[5-(2-metilfenil)-2-propil-1H-imidazol-4-il]piridina, ii) 2-[2-(1,1-dimetiletil)-5-(4-metoxifenil)-1H-imidazol-4- il]piridina, iii) 2-[2-(1,1-dimetiletil)-5-fenil-1H-imidazol-4-il]piridina,iv) 2-[5-(3,5-diclorofenil)-2-metil-1H-imidazol-4-il]piridina, v) 2-[5-(3,5-dimetilfenil)-2-metil-1H-imidazol-4-il]piridina, vi) 2-[5-(3,5-dimetilfenil)-2-etil-1H-imidazol-4-il]piridina, vii) 2-[5-(3,5-dimetilfenil)-2-amino-1H-imidazol-4-il]piridina, viii) 2-[5-(3,5-dimetilfenil)-2-isopropil-1H-imidazol-4- il]piridina, ix) 2-[5-(3,5-dimetilfenil)-2-propil-1H-imidazol-4-il]piridina, o x) 2-[5-(3,5-dimetilfenil)-2-carboxamida-1H-imidazol-4- il]piridina. Un método para inhibir la ruta que transmite la señal del TGF- ß en los mamíferos, que comprende administrar a un mamífero que necesita de tal tratamiento, una cantidad terapéuticamente eficaz de un compuesto según una cualquiera de las reivindicaciones 1 a 6, pero sin las condiciones i) a x), o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004053A GB0004053D0 (en) | 2000-02-21 | 2000-02-21 | Compounds |
| GB0015902A GB0015902D0 (en) | 2000-06-28 | 2000-06-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5271680A1 true CO5271680A1 (es) | 2003-04-30 |
Family
ID=26243690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01013429A CO5271680A1 (es) | 2000-02-21 | 2001-02-20 | Compuestos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030166633A1 (es) |
| EP (1) | EP1257543A1 (es) |
| JP (1) | JP2003524010A (es) |
| KR (1) | KR20020073597A (es) |
| CN (1) | CN1404478A (es) |
| AR (1) | AR029803A1 (es) |
| AU (2) | AU2001233918B2 (es) |
| BR (1) | BR0108437A (es) |
| CA (1) | CA2401036A1 (es) |
| CO (1) | CO5271680A1 (es) |
| CZ (1) | CZ20022852A3 (es) |
| HU (1) | HUP0204514A3 (es) |
| IL (1) | IL151319A0 (es) |
| MX (1) | MXPA02008082A (es) |
| NO (1) | NO20023953L (es) |
| NZ (1) | NZ520753A (es) |
| PL (1) | PL357420A1 (es) |
| WO (1) | WO2001062756A1 (es) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002225730A1 (en) * | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| GB0127433D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| JP2005530800A (ja) * | 2002-05-15 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール |
| AU2003256783A1 (en) * | 2002-07-25 | 2004-02-16 | Scios, Inc. | METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS |
| US20040146509A1 (en) * | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| AP2005003262A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors. |
| ES2325687T3 (es) | 2002-09-18 | 2009-09-14 | Pfizer Products Inc. | Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf). |
| HRP20050251A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tfg) inhibitors |
| WO2004026863A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
| DE60330362D1 (de) | 2002-09-18 | 2010-01-14 | Pfizer Prod Inc | Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| EP1723146A1 (en) * | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| NZ549003A (en) | 2004-03-05 | 2009-07-31 | Taisho Pharmaceutical Co Ltd | Thiazole derivative as an ALK5 inhibitor |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| EP1798229A4 (en) * | 2004-09-07 | 2009-07-29 | Sankyo Co | SUBSTITUTED BIPHENYL DERIVATIVE |
| CN101223161A (zh) * | 2005-06-24 | 2008-07-16 | 健亚生物科技公司 | 治疗病毒感染的杂芳基衍生物 |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| PL2170396T3 (pl) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Limited | Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| TWI410425B (zh) * | 2010-12-03 | 2013-10-01 | Lilly Co Eli | 唑并［５，４－ｂ］吡啶－５－基化合物 |
| CA2841252C (en) | 2011-07-13 | 2019-02-26 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| KR102022715B1 (ko) * | 2011-07-29 | 2019-09-18 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 핵 수송 조절인자 및 이의 용도 |
| SMT201800171T1 (it) | 2011-07-29 | 2018-07-17 | Karyopharm Therapeutics Inc | Modulatori di trasporto nucleare contenenti idrazide e loro usi |
| MX364992B (es) | 2012-05-09 | 2019-05-17 | Biogen Ma Inc | Moduladores del transporte nuclear y usos de los mismos. |
| WO2013181326A1 (en) | 2012-05-30 | 2013-12-05 | Cornell University | Generation of functional and durable endothelial cells from human amniotic fluid-derived cells |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| CA2901747A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| JP6529486B2 (ja) | 2013-06-05 | 2019-06-12 | バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． | 哺乳動物種における誘導組織再生のための組成物および方法 |
| US9738624B2 (en) | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| JP6513105B2 (ja) | 2014-04-22 | 2019-05-15 | ウニヴェルズィテート バーゼル | トリアジン、ピリミジン及びピリジン誘導体の新規製造方法 |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| EP4112615A1 (en) | 2014-08-15 | 2023-01-04 | Karyopharm Therapeutics Inc. | Compositions comprising one crystalline form of selinexor |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2017100313A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derive brown fat cells |
| MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| KR102434226B1 (ko) | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| WO2018132279A1 (en) * | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CN110494166B (zh) | 2017-05-02 | 2022-11-08 | 诺华股份有限公司 | 组合疗法 |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| BR112021011224A2 (pt) | 2018-12-11 | 2021-08-24 | Theravance Biopharma R&D Ip, Llc | Inibidores de alk5 |
| KR20210117271A (ko) | 2018-12-21 | 2021-09-28 | 노쓰웨스턴유니버시티 | 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용 |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| CN113330012A (zh) * | 2019-01-22 | 2021-08-31 | 比西切姆有限公司 | 作为alk4/5抑制剂的稠环杂芳基化合物 |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| EP3999501A1 (en) * | 2019-07-16 | 2022-05-25 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| JP2023502662A (ja) * | 2019-11-22 | 2023-01-25 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン |
| WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| WO2022006340A1 (en) * | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| FI4182308T3 (fi) | 2020-07-15 | 2024-12-07 | Chiesi Farm Spa | Pyridatsinyyliaminojohdannaisia alk5-estäjinä |
| WO2022013311A1 (en) | 2020-07-15 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| US20240190891A1 (en) | 2020-07-15 | 2024-06-13 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine amino derivatives as alk5 inhibitors |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| CN118201915A (zh) | 2021-09-21 | 2024-06-14 | 奇斯药制品公司 | 作为alk5抑制剂的哒嗪基氨基衍生物 |
| CN114380823B (zh) * | 2022-01-26 | 2023-06-23 | 中国药科大学 | 咪唑-2-甲胺类衍生物及其医药用途 |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| CN116891472A (zh) * | 2023-07-13 | 2023-10-17 | 延边大学 | 一种含咪唑结构的酰胺类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH561716A5 (es) * | 1971-05-10 | 1975-05-15 | Ciba Geigy Ag | |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| WO1995003297A1 (en) * | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| JPH09124640A (ja) * | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | ピリジルイミダゾール化合物、製法および農園芸用殺菌剤 |
| IL133766A0 (en) * | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
-
2001
- 2001-02-20 AR ARP010100755A patent/AR029803A1/es not_active Application Discontinuation
- 2001-02-20 CO CO01013429A patent/CO5271680A1/es not_active Application Discontinuation
- 2001-02-21 WO PCT/GB2001/000736 patent/WO2001062756A1/en not_active Ceased
- 2001-02-21 AU AU2001233918A patent/AU2001233918B2/en not_active Ceased
- 2001-02-21 NZ NZ520753A patent/NZ520753A/en unknown
- 2001-02-21 PL PL01357420A patent/PL357420A1/xx not_active Application Discontinuation
- 2001-02-21 BR BR0108437-2A patent/BR0108437A/pt not_active IP Right Cessation
- 2001-02-21 IL IL15131901A patent/IL151319A0/xx unknown
- 2001-02-21 EP EP01905954A patent/EP1257543A1/en active Pending
- 2001-02-21 HU HU0204514A patent/HUP0204514A3/hu unknown
- 2001-02-21 AU AU3391801A patent/AU3391801A/xx active Pending
- 2001-02-21 US US10/204,370 patent/US20030166633A1/en not_active Abandoned
- 2001-02-21 CN CN01805374A patent/CN1404478A/zh active Pending
- 2001-02-21 MX MXPA02008082A patent/MXPA02008082A/es unknown
- 2001-02-21 CZ CZ20022852A patent/CZ20022852A3/cs unknown
- 2001-02-21 KR KR1020027010853A patent/KR20020073597A/ko not_active Withdrawn
- 2001-02-21 CA CA002401036A patent/CA2401036A1/en not_active Abandoned
- 2001-02-21 JP JP2001562538A patent/JP2003524010A/ja active Pending
-
2002
- 2002-08-20 NO NO20023953A patent/NO20023953L/no not_active Application Discontinuation
-
2004
- 2004-01-29 US US10/767,943 patent/US20040220230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL151319A0 (en) | 2003-04-10 |
| EP1257543A1 (en) | 2002-11-20 |
| WO2001062756A1 (en) | 2001-08-30 |
| CA2401036A1 (en) | 2001-08-30 |
| BR0108437A (pt) | 2005-06-28 |
| CZ20022852A3 (cs) | 2003-04-16 |
| KR20020073597A (ko) | 2002-09-27 |
| HUP0204514A2 (en) | 2003-05-28 |
| PL357420A1 (en) | 2004-07-26 |
| JP2003524010A (ja) | 2003-08-12 |
| AU3391801A (en) | 2001-09-03 |
| AU2001233918B2 (en) | 2004-06-24 |
| CN1404478A (zh) | 2003-03-19 |
| US20030166633A1 (en) | 2003-09-04 |
| MXPA02008082A (es) | 2003-02-27 |
| NZ520753A (en) | 2004-08-27 |
| US20040220230A1 (en) | 2004-11-04 |
| AR029803A1 (es) | 2003-07-16 |
| NO20023953L (no) | 2002-10-21 |
| NO20023953D0 (no) | 2002-08-20 |
| HUP0204514A3 (en) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5271680A1 (es) | Compuestos | |
| PE20230820A1 (es) | Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead | |
| ATE168673T1 (de) | Kondensierte pyrrolcarboxanilide; eine neue klasse von gaba-gehirn-rezeptor-liganden | |
| CO5170518A1 (es) | Compuestos n-(benzocicloalquilo) derivados de amino aralifaticos | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| BR9307595A (pt) | Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis | |
| CO5080782A1 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa | |
| HRP20030281B1 (en) | Pesticidal composition | |
| CO5090835A1 (es) | Biciclo [2.2.1] heptanos y compuestos relacionados | |
| AR106929A2 (es) | Procedimiento para sintetizar compuestos útiles para tratar hepatitis c | |
| NO2012021I2 (no) | Perampanel eller salter eller hydrater derav | |
| PE20021002A1 (es) | Compuestos heterociclicos condensados | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| EA200901659A1 (ru) | Соединения пиперазина с гербицидным действием | |
| AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
| NO20023456D0 (no) | Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme | |
| CO5700733A2 (es) | Acidos aminocarboxilicos sustituidos | |
| UY25987A1 (es) | Procedimiento para preparar complejo del inhibidor de ras-fa rnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2- hidroxipropil-beta-ciclodextrina y método | |
| DE69923692D1 (de) | Wachstumshormon-freisetzende oxindolderivate | |
| CO5200792A1 (es) | Derivados de n,5-dimetil-4-fenil-n-prop-2-in-1-il-1,3-tiazol-2-amina | |
| AR024423A1 (es) | PROCESO PARA LA PREPARACIoN DE TIAMETOXAM. | |
| FI890520A0 (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2- (piperidin-4-ylmetyl) -1,2,3,4 -tetrahydroisokinolinderivat. | |
| DK304289A (da) | Benzenderivater | |
| NZ504316A (en) | Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists | |
| CO5221057A1 (es) | Componentes y composiciones plagicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |